Screening of Bioactive Compounds against Nonreceptor Fyn Kinase: Virtual Screening and Network Approach

Sudharsana sundarrajan, Thabitha Amalraj, Sweta Kumari, Sajitha Lulu, Mohanapriya Arumugam


Tyrosine phosphorylation is a key controlling mechanism in signal transduction and enzyme activity regulation. Dysfunction of Fyn kinase, a unique member of non-receptor Src kinase family is implicated in oncogenesis, T-cell mediated diseases and neuronal disorders. Fyn kinase has been recognized as an important target for anti-cancer therapeutics. An insilico virtual screening of open and closed states of Fyn with seventy phytochemicals used in cancer treatment was carried out.  Molecular properties and bioactive spectrum analysis further improved the screening process by forming a data set containing seven potential hits. Ligand efficiency score which combines biological and chemical space together identified three secondary metabolites apigenin, genistein and quercetin as efficient inhibitors of Fyn kinase.  A reverse virtual screening approach validated the target selection by identifying Src kinase family members as potential drug targets. Drug-target interaction network based on feature scores of 22 phytochemicals which survived the initial screening process further validated our findings.  A conceptual optimization may be required to reduce attrition and increase the activity of the lead.


Fyn kinases Src kinase Oncogenesis Ligand efficiency Reverse virtual screening Feature score Drug-target network

Full Text:



Daniela SK, Richard AV., Tyrosine Kinases as Targets for Cancer Therapy, N ENGL J Med, 2005; 353: 172-187

Manash KP, Anup KM., Tyrosine kinases – Role and Significance in Cancer. Int. J. Med. Sci, 2004; 1: 101-115

Dan RR, Yi-Mi WU, Su-Fang L., The Protein Tyrosine Kinase Family of the Human Genome. Oncogene, 2000; 19: 5548-5557

Marilyn DR., Fyn, A SRC Family Tyrosine Kinase. Int J Biochem Cell Biol, 1998; 30: 1159-1162

Evan I., Src Family Kinases: Regulation of their activities, levels and identification of new pathways. Biochim Biophys Acta, 2008; 1784: 56–65

Dominik F, Behrouz M, Alessandra F, Kirishanthy K, Jenny Z, Ondrej B, Dominique D, Andre V, Michael J., Lck-dependent Fyn Activation Requires C Terminus-dependent Targeting of Kinase-active Lck to Lipid Rafts. J Biol Chem, 2008; 283: 26409–26422

Sali A, Blundell TL., Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol, 1993; 234: 779-815.

Stephen FA, Warren G, Webb M, Eugene WM, David JL., Basic local alignment search tool. J. Mol. Biol, 1990; 215: 403-410

Laskowski RA, MacArthur MW, Moss DS, Thornton JM., PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Cryst, 1993; 26: 283-291

Markus W, Manfred JS., ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins. Nucleic Acids Res, 2007; 35: W407–W410

Pascal B, Michael K, Torsten S., QMEAN server for protein model quality estimation. Nucleic Acids Res, 2009; 1: 510-W514

Bolton E, Wang Y, Thiessen PA, Bryant SH., PubChem: Integrated Platform of Small Molecules and Biological Activities. Chapter 12 IN Annual Reports in Computational Chemistry, vol 4, American Chemical Society, Washington, DC

Priyanka J, Vipin AM, Silpa S, Priya AP, Parvathi S, Raghunath K, Puthiyaveetil AN., DIACAN: Integrated Database for Antidiabetic and Anticancer medicinal Plants. Bioinformation, 2013; 9: 941-943

Ingo M, Scott O.,Advances in virtual screening. Drug Discov Today: Insilico techniques, 2006; 3: 405-411

Trott O, Olson AJ., AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. J Comput Chem, 2010; 31: 455-461

Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ., Autodock4 and AutoDockTools4: automated docking with selective receptor flexiblity. J. Comput Chem, 2009; 16: 2785-2791.

Stefano F., Raccoon|AutoDock VS: an automated tool for preparing AutoDock virtual screenings. 2010

Filimonov D, Poroikov V., Bioactive compound design: Possibilities for industrial use. PASS: Computerized prediction of biological activity spectra for chemical substances. BIOS Scientific Publishers, 1996;44-56

Liu X, Ouyang S, Yu B, Liu Y, Huang K, Gong J, Zheng S, Li Z, Li H, Jiang H., PharmMapper server: a web server for potential drug target identification using pharmacophore mapping approach. Nucleic Acids Res, 2010; 1: W609-W614

Paul S, Andrew M, Owen O, Nitin SB, Jonathan TW, Daniel R, Nada A, Benno S, Trey I., Cytoscape: a software for integrated models of biomolecular interaction networks. Genome Res, 2001; 13: 2498-2504

Dubravko J, Boris M, Sanja K, Krunoslav N, Donatalla V, Ognjen C, Roberto A, Wolfganag B., Homology modeling of human Fyn Kinase structure: Discovery of Rosmarinic acid as a new Fyn Kinase inhibitor and in silico study of its possible binding modes. J. Med. Chem, 2007; 50: 1090-1100

Lipinski CA, Lombardo F, Dominy BW, Feeney PJ., Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev, 2001; 46: 3–26

Cele AZ., Ligand efficiency indicies for effective drug discovery. Expert Opin. Drug Discov, 2007; 2:469-488

Peter C, Tamas K, Huba J.M, Gabor L, Ruth N., Structure and dynamics of molecular networks: A novel paradigm of drug discovery a comprehensive review. Pharmacol Ther, 2013; 138:333–408.